AlphAIAlphAI — Financial news for AI agents
investing.com$VIR

Vir Biotech earnings beat by $0.17, revenue fell short of estimates

Vir Biotech (VIR) reported Q3 EPS of -$0.57, beating estimates by $0.17, but revenue of -$188K missed expectations of $865.13K. The stock is up 33.45% in 3 months and 117.96% in 12 months, with a 'good performance' financial health score according to InvestingPro.

Original reporting
investing.com
Published Nov 5, 2026, 12:14 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 12:23 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$VIR
Bullish
medium confidence
Mentioned
$VIR
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$VIRBullishMed
01

Why it matters

Earnings beat on EPS provides a short‑term catalyst, but revenue shortfall may limit sustained rally.

02

Market read

The earnings surprise offers a modest trading opportunity for risk‑tolerant investors in the biotech space.

03

What to watch

Cash burn and upcoming pipeline milestones could dominate future price action.

Relevance 7/10Novelty 7/10Timing: post‑market today

Background

Vir Biotech is a micro‑cap biotech listed on NASDAQ, known for early‑stage drug development.

Company-level read

Ticker impact

$VIRBullishMedium confidence
Context

Vir Biotech reported Q3 EPS of $-0.57, beating estimates by $0.17, while revenue missed expectations.

Expected impact

likely modest upside as the market prices in the EPS beat

Evidence & confidence

EPS beat is a fresh, material data point; revenue miss tempers enthusiasm, so impact is limited.

Market effects

Sector

Biotech sector may see slight uplift as earnings beat highlights potential resilience.

Regional

U.S. small‑cap biotech investors could adjust positions.

Global

Limited to niche biotech investors.

Counterpoint

What could challenge this read

Revenue miss suggests underlying demand weakness; the EPS beat may be a one‑off accounting effect.

Key entities

  • Company
    Vir Biotech

    NASDAQ‑listed biotech firm reporting Q3 results.

Read at source← All news

StoryVir Biotechnology reports Q3 2026 results, announces Fast Track for VIR‑5500 and $90 M Gilead partnership

Also covered by

4 outlets

Related articles

$VIRMed

Vir Bio (VIR) Q3 2026 Earnings Call Transcript

Vir Bio (VIR) reported Q3 2026 progress, including Phase III hepatitis delta trials with data expected this quarter and next year. VIR-5500 received FDA Fast Track designation for late-line mCRPC. The company also announced a research collaboration with Gilead, validating its PRO-XTEN platform. VIR-5818's Phase I trial is ongoing with refined study design based on FDA feedback.

finance.yahoo.com
$VIRMed

What Vir Biotechnology (VIR) Said on Its Q3 Earnings Call

Vir Biotechnology (VIR) reported Q3 earnings, highlighting progress in its oncology pipeline. VIR-5500, a prostate cancer treatment, received FDA fast-track designation, with phase 3 trials planned for 2027. VIR-5818 and VIR-5525 are also advancing. The company secured a $90M deal with Gilead, including upfront payments and potential milestones. R&D expenses fell to $80M from $151M YoY, excluding a prior milestone payment.

finance.yahoo.com
$VIRMed

Vir Biotechnology 2026: Revenue ($188K), Net income ($96.25M), EPS ($0.57) — 10-Q Summary

Vir Biotechnology reported 2026 Q3 revenue of ($188K), a net loss of ($96.25M), and a diluted loss per share of ($0.57). This compares to revenue of $240K, a net loss of ($163.14M), and a diluted loss per share of ($1.17) in the prior-year period. The company is conducting clinical trials for several treatments, including ECLIPSE for CHD, with results expected in 2026-2027. Vir also has agreements with Gilead for solid-tumor T-cell engagers.

tradingview.com
$VIRMedAI 8/10

Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2026 Financial Results

Vir Biotechnology, Inc. (VIR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2026 Financial Results - Topline data from pivotal Phase 3 ECLIPSE 1 trial expected in the fourth quarter of 2026 - VIR-5500 received Fast Track designation and achieved proof of concept, with pivo

SEC EDGAR 8-K